返回 Agenda
[V2-S1] What is a Good Medical Communication?
Session Chair(s)
Lyo Inuyama, MD
Operating Officer, Head of Medical Affairs
Bayer Yakuhin, Ltd., Japan
To ensure proper drug use by medical experts and patients, communication to exchange drug information between the pharmaceutical industry and medical sites is indispensable. Currently, communication between the pharmaceutical industry, medical institutions, and patients covers a broad range including information dissemination on good use practice for GVP, benefit-risk communication focusing on RMP, Q&A through a Medical Information Office, actual published data, and academic information. This session will discuss the proper approach for good medical communication through comparison of communication on medical information in Europe and the US with that of Japan, the viewpoint within pharmaceutical industry, and expectations from medical sites.
Speaker(s)
The Current Status and Future Considerations of Medical Communications in Europe and the US
Stacey Fung, PharmD
Gilead Sciences, United States
Head, Global Medical Information
Current Status and Issues of Good Medical Communication Practice in Japan from Pharmacovigilance Perspectives
E. Stewart Geary, MD
Eisai Co., Ltd., Japan
MD, Global Safety Officer
Opportunities and Challenges in Medical Communication in Japan for Appropriate Drug Use
Hiroshi Tamada, MD, PhD, MBA
Bristol-Myers Squibb K.K., Japan
Senior Executive Officer, Head of Japan Medical & Development
Good Medical Communication: the Current Status and Issues (from the Clinical Practitioner Perspective)
Masatsugu Hori, MD, PhD, FACC
Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan
President-emeritus